8-K: NanoVibronix Subsidiary ENvue Medical Holdings Secures $360,000 Promissory Note

ENvue Medical Holdings, a subsidiary of NanoVibronix, Inc., has entered into a promissory note agreement for $360,000 with Alpha Capital Anstalt, guaranteed by NanoVibronix.

Summary

• ENvue Medical Holdings, a wholly-owned subsidiary of NanoVibronix, Inc., issued a promissory note to Alpha Capital Anstalt for $360,000 on April 11, 2025.
• The note matures on June 11, 2025, and carries an annual interest rate of 8.0%, payable in kind by adding accrued interest to the principal.
• Noteholders can require ENvue to redeem the note with proceeds from any issuance and sale of common stock or common stock equivalents by NanoVibronix.
• NanoVibronix has guaranteed ENvue's obligations under the note.
• The proceeds from the loan will be used for general corporate purposes.
• NanoVibronix has demonstrated compliance with Nasdaq listing requirements, but will be subject to a mandatory panel monitor for one year.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has secured funding and regained Nasdaq compliance, it has also taken on debt and is under monitoring.

Positives

• ENvue Medical Holdings has secured additional funding of $360,000.
• NanoVibronix has regained compliance with Nasdaq listing requirements.

Negatives

• The $360,000 promissory note adds to the debt obligations of ENvue Medical Holdings, guaranteed by NanoVibronix.
• NanoVibronix is under a mandatory panel monitor for one year, meaning any future non-compliance with Nasdaq equity rules will result in immediate delisting procedures.

Risks

• Failure to meet payment obligations under the promissory note could trigger an event of default.
• A bankruptcy event would cause the principal and accrued interest to become immediately due and payable.
• Continued non-compliance with Nasdaq listing rules could lead to delisting.

Future Outlook

The company will be subject to a mandatory panel monitor for a period of one year from April 9, 2025. If, within that one-year monitoring period, Staff finds the Company again out of compliance with the Equity Rule that was subject of the exception, the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3).

Industry Context

Many small cap companies rely on debt financing to fund operations and growth. The terms of this note, including the redemption right tied to equity issuance, are relatively common in such financings.

Comparison to Industry Standards

• The 8% interest rate is within the typical range for similar promissory notes issued by small-cap companies, but the rate can vary based on the company's creditworthiness and prevailing market conditions.
• The redemption right tied to equity issuance is a common feature in convertible debt or notes, allowing the lender to participate in potential upside from future equity offerings.
• Comparable companies in the medical device or technology space often utilize similar financing strategies, such as convertible notes or secured debt, to fund research and development or commercialization efforts.

Stakeholder Impact

• Shareholders may be impacted by potential dilution if the note is redeemed through the issuance of common stock or common stock equivalents.
• The funding provides ENvue Medical Holdings with capital to support its operations, potentially benefiting employees and customers.

Next Steps

• ENvue Medical Holdings will utilize the $360,000 for general corporate purposes.
• NanoVibronix will need to maintain compliance with Nasdaq listing rules during the one-year monitoring period.

Key Dates

Keywords

promissory note, guaranty, NanoVibronix, ENvue Medical Holdings, Alpha Capital Anstalt, debt, Nasdaq, compliance, funding